Centre Hospitalier Intercommunat nord Ardennes Hospital Pha	Residual volume in semi-rigid bags used to prepare anticancer drugs: myth or reality? Evaluation and impact in practice. <u>A.Hasoun Najar</u> , L.Josse, S.Martin, G.Leau, O.Gallon. Hospital Pharmacy Unit, Centre Hospitalier Intercommunal Nord Ardennes, Site de Charleville Mézières, 45 avenue de Manchester, 08000 Charleville Mézières, France				
Introduction : → Injectable anticancer (AC) drugs are pre- Hospital Center (CH), mainly by dilution in sen → Administration by the nurses using an infus → But a residual volume (Vr) persists at the of Objective: to measure the residual volume not administered to the patient.	 Materials and methods: → Recovery of preparations from 22, 23 and 24 May 2023 administered in the oncohaematology day hospital unit at the CH. → Sampling with a 10 mL syringe + bag perforator of residual volumes inside the isolator of 100- and 250-mL bags of NaCl and G5. → Comparison with controls without AC, the procedure was reproduced on 10 bags of NaCl 100mL and 250mL and 10 bags of G5 100 mL and 250 mL not reconstituted. 				
 Results: Sample analyzed = 42 bags of AC ✓ 15 bags of NaCl 100 mL ✓ 6 bags of G5 100 mL ✓ 6 bags of NaCl 250 mL ✓ 15 bags of G5 250 mL Of the 40 not reconstituted solvent bags ✓ Average Vr = 5.67 mL ✓ No significant difference according to solvent and/or initial volume. 	Average residual volume of AC bags = 5 mL No significant difference according to initial bag volume. Volume in mL remaining depending on the bag (100 or 250 mL) 0 0 6 10 15 20 25 10 15 20 25	Average residual of [min: 1.36%; max: \rightarrow For 100 mL bags = \rightarrow For 250 mL bags = Percentage of 8,00% 7,00% 6,00% 9,00% 0,00% 0 5 0 Percentage of 9,00% 0,00	dose of CA bags = 3% 6.84%]. 4.5 % 1.9 % dose remaining depending on the bag (100 or 250 mL) 0 15 20 25 tage of dose remaining in 100 mL bags	The 9 bags red equivalent to m were all 100mL => This repre preparation . Number of pro	covered with a remaining dose hore than 5% of the initial dose bags. esents 43% of this type of eparations according to percentage of residual dose

Discussion and conclusion:

Risk of under-dosing, particularly for 100 mL bags.

This number is probably underestimated because, despite the use of a syringe and a perforator, it was not possible to withdraw the entire residual volume.

Problem specific to bags and not dependent on the product added to the solvent = Risk to be extended to all reconstituted medicinal products, even outside oncology.

The risk is all the greater for **drugs with a narrow therapeutic range or in pediatrics.**

➔ This should lead us to change our practices

→ Switching to flexible solvent bags could reduce residual volume; this alternative will be studied shortly.